DNA
Ginkgo Bioworks Holdings Inc. Healthcare - Biotechnology Investor Relations →
Ginkgo Bioworks Holdings Inc. (DNA) closed at $6.71 as of 2026-03-20, trading 84.7% below its 200-week moving average of $43.71. This places DNA in the extreme value zone. The stock is currently moving closer to the line, down from -84.6% last week. The 14-week RSI sits at 36, indicating neutral momentum.
Trading volume is running at 1.1x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.98 ratio) is neutral — neither side is clearly dominating.
Over the past 208 weeks of data, DNA has crossed below its 200-week moving average 1 time. On average, these episodes lasted 208 weeks.
With a market cap of $416 million, DNA is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -51.1%. The stock trades at 0.8x book value.
Share count has increased 23.1% over three years, indicating dilution.
Over the past 4.1 years, a hypothetical investment of $100 in DNA would have grown to $4, compared to $152 for the S&P 500. DNA has returned -54.6% annualized vs 10.8% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: DNA vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After DNA Crosses Below the Line?
Across 1 historical episodes, buying DNA when it crossed below its 200-week moving average produced an average return of -68.0% after 12 months (median -68.0%), compared to -8.0% for the S&P 500 over the same periods. After 24 months, the average return was -72.0% vs +19.0% for the index.
Each line shows $100 invested at the moment DNA crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
DNA has crossed below its 200-week MA 1 time
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Mar 2022 | Ongoing | 208+ | 96.3% | Ongoing | -96.0% |
Frequently Asked Questions
Is DNA below its 200-week moving average?
Yes. As of 2026-03-20, Ginkgo Bioworks Holdings Inc. (DNA) is trading 84.7% below its 200-week moving average of $43.71. The current price is $6.71.
What is DNA's 200-week moving average price?
Ginkgo Bioworks Holdings Inc.'s 200-week moving average is $43.71 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when DNA drops below its 200-week moving average?
DNA has crossed below its 200-week moving average 1 time in our data. These episodes lasted 208 weeks on average.
Is DNA a good value right now?
Here's what our data says about DNA as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 36. Free cash flow is currently negative. Return on equity is -51.1%. Price-to-book is 0.8x. This is not a buy or sell recommendation — always do your own research.
How does DNA compare to the S&P 500?
Over the past 4.1 years, $100 invested in DNA would have grown to $4, compared to $152 for the S&P 500. That's -54.6% annualized vs 10.8% for the index. DNA has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20